Bimosiamose

Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects[1].

Product Specifications

CAS Number

[187269-40-5]

Product Name Alternative

TBC-1269

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

E-Selectin ; L-Selectin; P-selectin

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Bimosiamose.html

Purity

99.0

Solubility

0.1 M NaOH : 25 mg/mL (ultrasonic; adjust pH to 10 with NaOH) |DMSO : 100 mg/mL (ultrasonic)

Smiles

OC[C@H]([C@@H](O)[C@H](O)[C@@H]1O)O[C@@H]1OC(C=C2)=C(C3=CC(CC(O)=O)=CC=C3)C=C2CCCCCCC(C=C4)=CC(C5=CC(CC(O)=O)=CC=C5)=C4O[C@H]6O[C@@H]([C@@H](O)[C@H](O)[C@@H]6O)CO

Molecular Formula

C46H54O16

Molecular Weight

862.91

Precautions

H302, H315, H319, H335

References & Citations

[1]Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185 (4) :365-72.